Literature DB >> 19470512

Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding.

Chunquan Sheng1, Zhenyuan Miao, Haitao Ji, Jianzhong Yao, Wenya Wang, Xiaoying Che, Guoqiang Dong, Jiaguo Lü, Wei Guo, Wannian Zhang.   

Abstract

Cryptococcus neoformans is one of the most important causes of life-threatening fungal infections in immunocompromised patients. Lanosterol 14 alpha-demethylase (CYP51) is the target of azole antifungal agents. This study describes, for the first time, the 3-dimensional model of CYP51 from Cryptococcus neoformans (CnCYP51). The model was further refined by energy minimization and molecular-dynamics simulations. The active site of CnCYP51 was well characterized by multiple-copy simultaneous-search calculations, and four functional regions important for rational drug design were identified. The mode of binding of the natural substrate and azole antifungal agents with CnCYP51 was identified by flexible molecular docking. A G484S substitution mechanism for azole resistance in CnCYP51, which might be important for the conformation of the heme environment, is suggested.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470512      PMCID: PMC2715644          DOI: 10.1128/AAC.01630-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  [Cloning and expression of the mutant 14alpha-demethylase containing the alteration of H310D in Candida albicans and the preliminary study on its functions].

Authors:  Pinghui Gao; Yongbing Cao; Zheng Xu; Hongtao Liu; Yuanying Jiang
Journal:  Wei Sheng Wu Xue Bao       Date:  2003-12

2.  Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach.

Authors:  Elena Banfi; Giuditta Scialino; Daniele Zampieri; Maria Grazia Mamolo; Luciano Vio; Marco Ferrone; Maurizio Fermeglia; Maria Silvia Paneni; Sabrina Pricl
Journal:  J Antimicrob Chemother       Date:  2006-05-18       Impact factor: 5.790

3.  Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4.

Authors:  Erik Evensen; Diane Joseph-McCarthy; Gregory A Weiss; Stuart L Schreiber; Martin Karplus
Journal:  J Comput Aided Mol Des       Date:  2007-07-27       Impact factor: 3.686

4.  Functionality maps of binding sites: a multiple copy simultaneous search method.

Authors:  A Miranker; M Karplus
Journal:  Proteins       Date:  1991

5.  Structural and evolutionary studies on sterol 14-demethylase P450 (CYP51), the most conserved P450 monooxygenase: II. Evolutionary analysis of protein and gene structures.

Authors:  Y Yoshida; M Noshiro; Y Aoyama; T Kawamoto; T Horiuchi; O Gotoh
Journal:  J Biochem       Date:  1997-12       Impact factor: 3.387

6.  Generation of a complete, soluble, and catalytically active sterol 14 alpha-demethylase-reductase complex.

Authors:  D C Lamb; D E Kelly; K Venkateswarlu; N J Manning; H F Bligh; W H Schunck; S L Kelly
Journal:  Biochemistry       Date:  1999-07-06       Impact factor: 3.162

7.  The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans.

Authors:  Brendan J Loftus; Eula Fung; Paola Roncaglia; Don Rowley; Paolo Amedeo; Dan Bruno; Jessica Vamathevan; Molly Miranda; Iain J Anderson; James A Fraser; Jonathan E Allen; Ian E Bosdet; Michael R Brent; Readman Chiu; Tamara L Doering; Maureen J Donlin; Cletus A D'Souza; Deborah S Fox; Viktoriya Grinberg; Jianmin Fu; Marilyn Fukushima; Brian J Haas; James C Huang; Guilhem Janbon; Steven J M Jones; Hean L Koo; Martin I Krzywinski; June K Kwon-Chung; Klaus B Lengeler; Rama Maiti; Marco A Marra; Robert E Marra; Carrie A Mathewson; Thomas G Mitchell; Mihaela Pertea; Florenta R Riggs; Steven L Salzberg; Jacqueline E Schein; Alla Shvartsbeyn; Heesun Shin; Martin Shumway; Charles A Specht; Bernard B Suh; Aaron Tenney; Terry R Utterback; Brian L Wickes; Jennifer R Wortman; Natasja H Wye; James W Kronstad; Jennifer K Lodge; Joseph Heitman; Ronald W Davis; Claire M Fraser; Richard W Hyman
Journal:  Science       Date:  2005-01-13       Impact factor: 47.728

Review 8.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

9.  Estriol bound and ligand-free structures of sterol 14alpha-demethylase.

Authors:  Larissa M Podust; Liudmila V Yermalitskaya; Galina I Lepesheva; Vladimir N Podust; Enrique A Dalmasso; Michael R Waterman
Journal:  Structure       Date:  2004-11       Impact factor: 5.006

10.  Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.

Authors:  Chunquan Sheng; Wannian Zhang; Haitao Ji; Min Zhang; Yunlong Song; Hui Xu; Jie Zhu; Zhenyuan Miao; Qingfen Jiang; Jianzhong Yao; Youjun Zhou; Jü Zhu; Jiaguo Lü
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

View more
  23 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

4.  Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.

Authors:  Eveline Snelders; Anna Karawajczyk; Gijs Schaftenaar; Paul E Verweij; Willem J G Melchers
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 5.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

6.  Analysis of sphingolipids, sterols, and phospholipids in human pathogenic Cryptococcus strains.

Authors:  Ashutosh Singh; Andrew MacKenzie; Geoffrey Girnun; Maurizio Del Poeta
Journal:  J Lipid Res       Date:  2017-08-15       Impact factor: 5.922

7.  Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.

Authors:  Edward Sionov; Yun C Chang; H Martin Garraffo; Michael A Dolan; Mahmoud A Ghannoum; Kyung J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

8.  Novel mutations in CYP51B from Penicillium digitatum involved in prochloraz resistance.

Authors:  Jinlong Wang; Jinhui Yu; Jing Liu; Yongze Yuan; Na Li; Muqing He; Ting Qi; Geng Hui; Li Xiong; Deli Liu
Journal:  J Microbiol       Date:  2014-08-02       Impact factor: 3.422

Review 9.  Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.

Authors:  F P Gullo; S A Rossi; J de C O Sardi; V L I Teodoro; M J S Mendes-Giannini; A M Fusco-Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

10.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.